Stock Events

Incyte 

€65.42
101
+€5.4+9% Tuesday 13:36

Statistics

Day High
65.42
Day Low
60.6
52W High
-
52W Low
-
Volume
750
Avg. Volume
-
Mkt Cap
12.65B
P/E Ratio
160.15
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
-1.82
-0.83
0.15
1.14
Expected EPS
1.05117
Actual EPS
1.07

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ICY.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap179.38B
Amgen competes with Incyte in the biopharmaceutical sector, focusing on innovative therapeutics in areas overlapping with Incyte's interests, such as oncology and inflammation.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences operates in similar therapeutic areas as Incyte, including oncology and antiviral drugs, making them direct competitors in the market for cancer and other treatments.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Incyte in the development of cancer treatments and immunotherapies, areas where Incyte is also heavily invested.
Merck
MRK
Mkt Cap300.25B
Merck is a leading pharmaceutical company that competes with Incyte in the oncology sector, particularly in the development and marketing of cancer treatments.
Novartis
NVS
Mkt Cap244.75B
Novartis competes with Incyte in multiple areas, including oncology and autoimmune diseases, with a broad portfolio that overlaps with Incyte's research and development focus.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is a global pharmaceutical giant that competes with Incyte in the development of drugs for various diseases, including cancer, which is a key focus area for Incyte.
Roche
RHHBY
Mkt Cap272.83B
Roche Holding AG competes with Incyte in the oncology and hematology fields, with a strong focus on developing innovative cancer treatments.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie competes with Incyte in the area of immunology and oncology, particularly in the development of treatments for cancers and autoimmune diseases.
Lilly(Eli) &
LLY
Mkt Cap864.43B
Eli Lilly and Company competes with Incyte in the pharmaceutical sector, focusing on areas such as oncology, which is a significant part of Incyte's business.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals is a competitor in the biopharmaceutical field, focusing on innovative treatments in areas like oncology and inflammatory diseases, directly competing with Incyte's research and product offerings.

Analyst Ratings

70.5Average Price Target
The highest estimate is €92.
From 13 ratings within the last 6 months. This is not an investment recommendation.
Buy
31%
Hold
62%
Sell
8%

About

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
Show more...
CEO
Mr. Herve Hoppenot
Employees
2524
Country
US
ISIN
US45337C1027
WKN
000896133

Listings